ES2373450T3 - Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c. - Google Patents

Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c. Download PDF

Info

Publication number
ES2373450T3
ES2373450T3 ES05815625T ES05815625T ES2373450T3 ES 2373450 T3 ES2373450 T3 ES 2373450T3 ES 05815625 T ES05815625 T ES 05815625T ES 05815625 T ES05815625 T ES 05815625T ES 2373450 T3 ES2373450 T3 ES 2373450T3
Authority
ES
Spain
Prior art keywords
cyclosporine
carbon atoms
hepatitis
same
branched chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05815625T
Other languages
English (en)
Spanish (es)
Inventor
Hans Georg Fliri
David Renwick Houck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCYNEXIS Inc
Scynexis Inc
Original Assignee
SCYNEXIS Inc
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCYNEXIS Inc, Scynexis Inc filed Critical SCYNEXIS Inc
Application granted granted Critical
Publication of ES2373450T3 publication Critical patent/ES2373450T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES05815625T 2004-10-01 2005-09-30 Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c. Expired - Lifetime ES2373450T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61515204P 2004-10-01 2004-10-01
US615152P 2004-10-01
US70762605P 2005-08-11 2005-08-11
US707626P 2005-08-11
PCT/US2005/035533 WO2006039668A2 (en) 2004-10-01 2005-09-30 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Publications (1)

Publication Number Publication Date
ES2373450T3 true ES2373450T3 (es) 2012-02-03

Family

ID=36143148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05815625T Expired - Lifetime ES2373450T3 (es) 2004-10-01 2005-09-30 Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c.

Country Status (19)

Country Link
US (2) US20100167996A1 (OSRAM)
EP (1) EP1802650B1 (OSRAM)
JP (2) JP5139065B2 (OSRAM)
KR (1) KR101309409B1 (OSRAM)
CN (1) CN101773661B (OSRAM)
AT (1) ATE530561T1 (OSRAM)
AU (1) AU2005292162B2 (OSRAM)
BR (1) BRPI0516737A (OSRAM)
CA (1) CA2583494C (OSRAM)
DK (1) DK1802650T3 (OSRAM)
ES (1) ES2373450T3 (OSRAM)
IL (1) IL182315A (OSRAM)
MX (1) MX2007003538A (OSRAM)
NZ (1) NZ554514A (OSRAM)
PL (1) PL1802650T3 (OSRAM)
PT (1) PT1802650E (OSRAM)
RU (1) RU2399628C2 (OSRAM)
SI (1) SI1802650T1 (OSRAM)
WO (1) WO2006039668A2 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
KR20080059270A (ko) * 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
CN101305019B (zh) 2005-10-26 2012-12-12 安斯泰来制药有限公司 新的环肽化合物
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
EP2073831A1 (en) * 2006-10-12 2009-07-01 Novartis AG Use of modified cyclosporins
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
BRPI0810203A2 (pt) 2007-05-02 2014-10-14 Astellas Pharma Inc Compostos peptídeos cíclicos.
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20130190223A1 (en) 2008-07-30 2013-07-25 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
CA2750227A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
KR20110111321A (ko) * 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
NZ599963A (en) * 2009-12-18 2014-02-28 Boehringer Ingelheim Int Hcv combination therapy
JP2013516424A (ja) 2009-12-30 2013-05-13 サイネクシス，インコーポレーテッド シクロスポリン類似体
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
WO2012075494A1 (en) * 2010-12-03 2012-06-07 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
RU2448690C1 (ru) * 2011-03-15 2012-04-27 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма пролонгированного действия нестероидного противовоспалительного средства кетопрофен, способ получения
WO2013028615A2 (en) * 2011-08-19 2013-02-28 S&T Golbal Inc. Novel cyclosporin derivatives for the treatment and prevention of viral infections
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9221878B2 (en) * 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
WO2016160362A1 (en) 2015-03-31 2016-10-06 Allergan, Inc. Cyclosporins modified on the mebmt sidechain by heterocyclic rings
US10738084B2 (en) * 2015-06-30 2020-08-11 Sentry Therapeutics Limited Macrocycles
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
WO2021068957A1 (en) 2019-10-12 2021-04-15 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
BR112022018929A2 (pt) 2020-03-26 2022-12-06 Farsight Medical Tech Shanghai Co Ltd Inibidores da ciclofilina e seus usos
EP4135743A4 (en) * 2020-04-15 2024-05-22 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
US5863550A (en) * 1993-03-31 1999-01-26 Tokyo Tanabe Company Limited Cholestasis ameliorant
AU688344B2 (en) * 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
US5739105A (en) * 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
DE59608274D1 (de) * 1995-07-17 2002-01-03 Chem Ag Binningen C Cyclosporin-derivate mit anti-hiv-wirkung
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
BR9911160A (pt) * 1998-06-12 2001-04-03 Chem Ag C Ciclosporinas
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
EP1091975B1 (fr) * 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2007041631A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
KR20080059270A (ko) * 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
JP5377293B2 (ja) * 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) * 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
CN102271688A (zh) * 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv的环孢菌素衍生物和核苷的组合
CA2750227A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2011070364A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Also Published As

Publication number Publication date
PL1802650T3 (pl) 2012-04-30
DK1802650T3 (da) 2012-02-06
EP1802650A2 (en) 2007-07-04
JP5139065B2 (ja) 2013-02-06
PT1802650E (pt) 2011-12-30
HK1108703A1 (en) 2008-05-16
BRPI0516737A (pt) 2008-04-29
EP1802650B1 (en) 2011-10-26
CN101773661B (zh) 2013-09-25
WO2006039668A3 (en) 2007-04-19
WO2006039668A2 (en) 2006-04-13
CN101773661A (zh) 2010-07-14
AU2005292162B2 (en) 2011-11-10
US20100167996A1 (en) 2010-07-01
AU2005292162A1 (en) 2006-04-13
JP2008514732A (ja) 2008-05-08
RU2007116119A (ru) 2008-11-10
KR20070073841A (ko) 2007-07-10
SI1802650T1 (sl) 2012-03-30
IL182315A0 (en) 2007-07-24
KR101309409B1 (ko) 2013-09-23
EP1802650A4 (en) 2008-08-20
IL182315A (en) 2013-08-29
MX2007003538A (es) 2008-01-16
NZ554514A (en) 2010-10-29
ATE530561T1 (de) 2011-11-15
RU2399628C2 (ru) 2010-09-20
CA2583494C (en) 2014-01-21
JP2012167113A (ja) 2012-09-06
CA2583494A1 (en) 2006-04-13
WO2006039668B1 (en) 2007-05-31
US20120264679A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
ES2373450T3 (es) Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c.
US7718767B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7576057B2 (en) Cyclic peptides
JP5322647B2 (ja) ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
RU2440822C2 (ru) Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с
US20090306033A1 (en) Novel cyclic peptides
ES2306924T3 (es) Peptidomimeticos fijados a una matriz como medicamentos contra el vih y el cancer.
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
US20120010131A1 (en) Novel cyclosporin analogues
HK1108703B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection